Attralus buys in brain shuttle tech to cross blood-brain barrier

Amyloidosis-focused biopharma Attralus and Ossianix, an antibody engineering company developing a single domain antibody platform (VNARs) to deliver molecules across the blood-brain barrier (BBB), have agreed a deal.

The agreement gives Attralus access to Ossianix' brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s disease.

"The addition of the TXP1 brain shuttle has the potential to significantly improve CNS penetration and efficacy"Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.